Sales & Support: 314-485-5210



Catalogue number:
1 mg
Product is available in:
  • USA
  • Canada
$50.00 Shipping is calculated in checkout

Kinase inhibitor (pan specific). Inhibits MARK2/3, which interact with SARS-CoV-2 Orf9b. Gordon et al. bioRxiv, Mar 23 2020, https://doi.org/10.1101/2020.03.22.002386.

  • Datasheet:   view or download
  • Applications:Approved drug (U.S.) that could be repurposed
Product Type:

Biochemicals & reagents

CAS Number:



1) Odgerel, et al. (2008) The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. Oncogene 27 3102 / 2) El Fitori, et al., (2007) PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer Cancer 110 1457 / Miyatake, et al. ( 2007) PKC412 (CGP41251) modulates the proliferation and lipopolysaccharide-induced inflammatory responses of RAW 264.macrophages: Biochem. Biophys. Res. Commun. 360 115 / 4) Bahlis et.al. (2005) N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells Leuk. Lymphoma 46 899 / 5) Fabbro et al., (2000) PKC-412 – a protein kinase inhibitor with a broad therapeutic potential; Anticancer Drug Des. 15 17

Limit of Detection:


Storage Temperature:

Room Temperature

Additional Information:

PKC-412 is a broad spectrum kinase inhibitor which include, but are not limited to; PKA, PKC, S6 Kinase, KDR, PKC, Akt, EGFR, VEGFR, PDGFR, c-kit, and FLT-3. The acute myeloid leukemia related mutant forms of FLT-3 are also inhibited both in vitro and in vivo by this compound. PKC-412 has been demonstrated to induce apoptosis and shows broad antiproliferative activity in various tumor cell lines and is also cell permeable.